NCT02092324View on ClinicalTrials.gov

Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 8, 2014

Primary Completion Date

November 22, 2019

Study Completion Date

January 24, 2020

Conditions
Atypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Neutrophilic Leukemia
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Ruxolitinib Phosphate

Given PO

Trial Locations (7)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

63110

Washington University School of Medicine, St Louis

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

77030

M D Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

94304

Stanford Cancer Institute Palo Alto, Palo Alto

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
lead

OHSU Knight Cancer Institute

OTHER

NCT02092324 - Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia | Biotech Hunter | Biotech Hunter